ECONOMIA DELLINNOVAZIONE NELLINDUSTRIA FARMACEUTICA parte I Prof Stefano

ECONOMIA DELL’INNOVAZIONE NELL’INDUSTRIA FARMACEUTICA parte I Prof. Stefano Capri Istituto di Economia Università Carlo Cattaneo-LIUC S. Capri - LIUC University

S. Capri - LIUC University

S. Capri - LIUC University

S. Capri - LIUC University

S. Capri - LIUC University

S. Capri - LIUC University

S. Capri - LIUC University

S. Capri - LIUC University

Top worldwide pharmaceutical companies S. Capri - LIUC University

Revenue drivers • • R&D pipeline New drugs introduction rate Sales network Relationship network S. Capri - LIUC University

Cost drivers • R&D • Promotion • Salesnetwork S. Capri - LIUC University

S. Capri - LIUC University

Promotion S. Capri - LIUC University

Competitive environment • The increase of cost and length of the R&D process • The increase of internal competition • The advent of generic medicines • The expiration of patents • The price regulation • The advent of personalised medicines S. Capri - LIUC University

From Laboratory to Patient: The Complex Pathway of Biopharmaceutical R&D Pharmaceutical Industry Profile 2005 (Washington, DC: Ph. RMA, March 2005). S. Capri - LIUC University

Biopharmaceutical R&D Expenditures and NIH Budget: 1994– 2004 S. Capri - LIUC University Pharmaceutical Industry Profile 2005 (Washington, DC: Ph. RMA, March 2005).

The period of market exclusivity between the introduction of a breakthrough medicine and of a competing product is rapidly shrinking S. Capri - LIUC University

The expiration of patents Generic “erosion” S. Capri - LIUC University

Price differences among European countries S. Capri - LIUC University